 (Genitourin Med 1995;71:244-246) 
Introduction
Azithromycin is an acid-stable orally administered macrolide antimicrobial drug, structurally related to erythromycin with a similar spectrum of antimicrobial activity.'2 Following oral administration, serum concentrations of azithromycin are lower than those of erythromycin, but this reflects the rapid movement of the drug from the circulation into intracellular compartments resulting in tissue concentrations exceeding those seen with erythromycin. 3 Azithromycin is subsequently slowly released, reflecting its long terminal phase elimination half-life, relative to that of erythromycin. These factors allow for a single dose therapy, a regimen that in chlamydial urethritis/cervicitis has been found as effective as erythromycin and other commonly used drugs administered for seven days. -8 The aim of this study was to determine the kinetics of a single oral 10 g dose of azithromycin in cervical mucus and plasma, and also to evaluate bacteriological efficacy and tolerance in women with chlamydial cervicitis.
Materials and methods A total of 20 women were included. All had a culture proven cervical chlamydial infection within the last week before inclusion. The patients were recruited at the out-patient venereal disease clinic of Copenhagen, after informed consent. The patients had not been treated with any antimicrobial agent within the preceding two weeks, had no known hypersensitivity to macrolides, or any known gastrointestinal, hepatic or renal disease.
A medical history including signs and symptoms of cervicitis, a cervical culture for Chlamydia trachomatis, cervical mucus, blood and urine samples together with standard laboratory tests were collected on day 0 before the oral intake of 1 g azithromycin in the clinic.
The patients were instructed to refrain from sexual intercourse until the end of the study, or, if not feasible, then to use a condom. The patients were asked to return for control visit on day 1, 7 and 14 where the medical history was updated, blood and cervical mucus were collected for determination of azithromycin concentration, cervical cultures for Chlamydia trachomatis (day 7 and 14) were performed, adverse events were recorded and blood for safety analysis was collected (day 7). Cervical samples were collected with cottontipped aluminium swabs.
Cervical mucus samples were collected by sucking the cervical canal with a syringetipped catheter. Mucus and plasma samples were stored in plain plastic tubes at -20°u ntil analysed. Azithromycin concentrations were determined by a high performance liquid chromatographic procedure (Huntingdon Research Centre Ltd, UK). Before the analysis of test samples, the analytical method was revalidated for plasma by the construction of a calibration line and by the analysis of spiked samples at three concentrations (low, medium and high) to establish intra (within)-batch accuracy. Owing to the nature of the samples of cervical mucus, it was not possible to construct calibration and quality control samples from that matrix. Calibrants were therefore prepared in dilute phosphate buffer (which was used to suspend the mucus samples prior to extraction) and the assay validated as for the plasma assay. The lower limit of quantification was set at 002,ug/ml for the plasma assay and 0.01 ,ug/ml for the cervical mucus assay, these being the lowest calibration datum point on the respective calibration lines. As the cervical mucus samples were too viscous or of insufficient volume to sample by volume, they were weighed and suspended in phosphate buffer before analysis. Azithromycin concentrations in mucus are therefore expressed as a weight basis as ,ug/g. Adverse effects were limited to mild gastrointestinal discomfort in three out of all 20 women. There were no major abnormal biochemical changes. The penetration of azithromycin to tissues in the genital tract has been demonstrated in prostatic and seminal fluid in healthy volunteers. '5 In that study azithromycin concentrations examined 24 hours after a single oral dose of 1 g azithromycin were much higher in prostatic fluid (mean 3.02 pg/ml) and in seminal fluid (2-39 ,ug/ml) than in plasma (007,ug/ml) with sustained concentrations after 48 hours. These data were taken as support for the efficacy of a single 1.0 g dose for chlamydial urethritis. The peripheral mucus and plasma concentrations after 24 hours in our study are very similar to the fluid and plasma concentrations in the latter study. '5 In order to further substantiate the theoretical evidence for a sustained tissue concentration at the site of infection, azithromycin concentrations were measured in cervical mucus as late as seven and 14 days after a single oral 1 g azithromycin dose in our study in women with chlamydial cervicitis.
Discussion
Technically it is difficult to suck cervical mucus if cervical secretion is minimal, which was the case in some women already the day after treatment and in almost all the women at day 7 
